Sign up to save your podcasts
Or
Share Björn Schimmöller - Inorganic Chemistry at the Frontier of Immunotherapy (FODD #15)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Björn Schimmöller - Inorganic Chemistry at the Frontier of Immunotherapy (FODD #15)
In this episode, we speak with Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
X: https://twitter.com/AntiverseHQ
View all episodes
In this episode, we speak with Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.
Host: Murat Tunaboylu, Co-Founder and CEO of Antiverse.
You will learn:
Things mentioned:
Additional Materials:
First time hearing about Antiverse?
Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.
For more information, please visit https://www.antiverse.io
Never miss a future event!
We'll notify you when a new event is scheduled. Fill out this form to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.
LinkedIn: https://www.linkedin.com/company/antiverse/
X: https://twitter.com/AntiverseHQ